Jazz Pharmaceuticals plc

DB:J7Z Stock Report

Market Cap: €7.3b

Jazz Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Bruce Cozadd

Chief executive officer

US$15.3m

Total compensation

CEO salary percentage7.8%
CEO tenure22yrs
CEO ownership0.5%
Management average tenure5.4yrs
Board average tenure11.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bruce Cozadd's remuneration changed compared to Jazz Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$463m

Jun 30 2024n/an/a

US$395m

Mar 31 2024n/an/a

US$331m

Dec 31 2023US$15mUS$1m

US$415m

Sep 30 2023n/an/a

US$80m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

-US$156m

Dec 31 2022US$17mUS$1m

-US$224m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$450m

Dec 31 2021US$16mUS$1m

-US$330m

Sep 30 2021n/an/a

-US$161m

Jun 30 2021n/an/a

US$40m

Mar 31 2021n/an/a

US$518m

Dec 31 2020US$13mUS$1m

US$239m

Sep 30 2020n/an/a

US$179m

Jun 30 2020n/an/a

US$133m

Mar 31 2020n/an/a

US$280m

Dec 31 2019US$15mUS$1m

US$523m

Sep 30 2019n/an/a

US$609m

Jun 30 2019n/an/a

US$656m

Mar 31 2019n/an/a

US$486m

Dec 31 2018US$11mUS$979k

US$447m

Compensation vs Market: Bruce's total compensation ($USD15.34M) is above average for companies of similar size in the German market ($USD3.31M).

Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.

CEO

Bruce Cozadd (60 yo)

22yrs

Tenure

US$15,341,235

Compensation

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...

Leadership Team

NamePositionTenureCompensationOwnership
Bruce Cozadd
Co-Founder22yrsUS$15.34m0.54%
€ 39.5m
Renee Gala
President & COO1.3yrsUS$5.43m0.028%
€ 2.0m
Patricia Carr
Senior VP & Chief Accounting Officer5.4yrsUS$1.40mno data
Neena Patil
Executive VP & Chief Legal Officer5.5yrsUS$3.88m0.012%
€ 885.0k
Robert Iannone
Executive VP5.7yrsUS$4.98m0.047%
€ 3.4m
Philip Johnson
Executive VP & CFOless than a yearno data0.020%
€ 1.4m
Andrea Flynn
VP & Head of Investor Relationsno datano datano data
Heidi Manna
Executive VP & Chief People Officer6.2yrsno datano data
Jed Black
Senior Vice President of Sleep & CNS Medicineno datano datano data
Samantha Pearce
Executive VP & Chief Commercial OfficerChief Commercial Officer4.8yrsno data0.011%
€ 768.2k
John Miller
Senior Vice President of Corporate Strategy5.3yrsno datano data
Mary Henderson
Senior Vice President of Technical Operations1.4yrsno data0.0021%
€ 153.8k

5.4yrs

Average Tenure

53yo

Average Age

Experienced Management: J7Z's management team is seasoned and experienced (5.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bruce Cozadd
Co-Founder22yrsUS$15.34m0.54%
€ 39.5m
Kenneth O'Keefe
Independent Director21yrsUS$513.77k0.046%
€ 3.3m
Seamus Mulligan
Independent Director13yrsUS$531.27k1.93%
€ 140.3m
Norbert Riedel
Independent Director11.7yrsUS$533.77k0.020%
€ 1.5m
Patrick Gerald Enright
Independent Director15.5yrsUS$526.27k0.035%
€ 2.5m
Patrick Kennedy
Independent Directorless than a yearno datano data
Rick Winningham
Lead Independent Director14.7yrsUS$571.27k0.015%
€ 1.1m
Jennifer Cook
Independent Non-Executive Director4.1yrsUS$533.77k0.0089%
€ 648.5k
Laura Hamill
Independent Directorless than a yearno data0.0025%
€ 179.9k
Heather McSharry
Independent Director11.7yrsUS$543.77k0.025%
€ 1.8m
Mark Smith
Independent Non-Executive Director4.1yrsUS$521.27k0.0089%
€ 648.5k
Anne O'Riordan
Independent Director5.9yrsUS$523.77k0.018%
€ 1.3m

11.7yrs

Average Tenure

61.5yo

Average Age

Experienced Board: J7Z's board of directors are seasoned and experienced ( 11.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 05:55
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jazz Pharmaceuticals plc is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Ishan MajumdarBaptista Research
Richard SilverBarclays